Improved treatment of community-acquired pneumonia through tailored interventions: Results from a controlled, multicentre quality improvement project.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 20 11 2019
accepted: 24 05 2020
entrez: 12 6 2020
pubmed: 12 6 2020
medline: 25 8 2020
Statut: epublish

Résumé

Community-acquired pneumonia (CAP) is one of the leading causes of healthcare utilisation and death worldwide. Treatment according to evidence-based clinical guidelines can reduce mortality, antibiotic exposure and length of hospital stay related to CAP. Several studies, including a pilot study from one of our sites, indicate that physicians show a low grade of guideline adherence when managing patients with CAP. To improve the guideline-based treatment of patients with CAP admitted to hospital, we designed a quality improvement study. Four process indicators were combined in a CAP care bundle: chest X-ray, CURB-65 severity score, lower respiratory tract samples and antibiotics within 8 hours from admission. After a 4-month baseline period, we applied multiple interventions at three hospitals during 8 months. Progression in our process indicators was measured continuously and compared with a control site without interventions. After the 8-month intervention period, we continued with a 4-month follow-up period to assess the sustainability of the improvements. The care bundle utilisation rate within 8 hours increased from 11% at baseline to 41% in the follow-up period at the intervention sites, whereas it remained below 3% at the control site. The most considerable improvements have been observed regarding documentation of CURB-65 (34% at baseline, 68% at follow-up) and the collection of lower respiratory tract samples (43% at baseline, 63% at follow-up). Our study has demonstrated poor adherence to CAP guidelines at all sites at baseline. After implementing multiple tailored interventions, guideline adherence increased substantially. In conclusion, we recommend that CAP guidelines should be actively adapted in order to be followed in a daily routine.

Sections du résumé

BACKGROUND
Community-acquired pneumonia (CAP) is one of the leading causes of healthcare utilisation and death worldwide. Treatment according to evidence-based clinical guidelines can reduce mortality, antibiotic exposure and length of hospital stay related to CAP.
LOCAL PROBLEM
Several studies, including a pilot study from one of our sites, indicate that physicians show a low grade of guideline adherence when managing patients with CAP.
METHODS
To improve the guideline-based treatment of patients with CAP admitted to hospital, we designed a quality improvement study. Four process indicators were combined in a CAP care bundle: chest X-ray, CURB-65 severity score, lower respiratory tract samples and antibiotics within 8 hours from admission. After a 4-month baseline period, we applied multiple interventions at three hospitals during 8 months. Progression in our process indicators was measured continuously and compared with a control site without interventions. After the 8-month intervention period, we continued with a 4-month follow-up period to assess the sustainability of the improvements.
RESULTS
The care bundle utilisation rate within 8 hours increased from 11% at baseline to 41% in the follow-up period at the intervention sites, whereas it remained below 3% at the control site. The most considerable improvements have been observed regarding documentation of CURB-65 (34% at baseline, 68% at follow-up) and the collection of lower respiratory tract samples (43% at baseline, 63% at follow-up).
CONCLUSION
Our study has demonstrated poor adherence to CAP guidelines at all sites at baseline. After implementing multiple tailored interventions, guideline adherence increased substantially. In conclusion, we recommend that CAP guidelines should be actively adapted in order to be followed in a daily routine.

Identifiants

pubmed: 32525882
doi: 10.1371/journal.pone.0234308
pii: PONE-D-19-32003
pmc: PMC7289425
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Controlled Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0234308

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Qual Health Care. 2014 Feb;26(1):100-7
pubmed: 24257160
Respir Med. 2014 Aug;108(8):1214-22
pubmed: 24898129
Thorax. 2012 Jan;67(1):71-9
pubmed: 20729232
Postgrad Med J. 2011 Oct;87(1032):670-9
pubmed: 21715571
Med J Aust. 2002 Nov 4;177(9):502-6
pubmed: 12405894
Int J Med Inform. 2016 May;89:55-62
pubmed: 26980359
Thorax. 2016 Nov;71(11):1061-1063
pubmed: 27534681
Int J Antimicrob Agents. 2008 Jan;31(1):3-11
pubmed: 17920819
Clin Infect Dis. 2004 Oct 1;39(7):955-63
pubmed: 15472846
JAMA Intern Med. 2014 Nov;174(11):1806-14
pubmed: 25201438
Chest. 2006 Sep;130(3):794-9
pubmed: 16963677
Eur J Clin Microbiol Infect Dis. 2005 Apr;24(4):241-9
pubmed: 15902529
Arch Intern Med. 2004 Mar 22;164(6):637-44
pubmed: 15037492
Infect Dis (Lond). 2018 Apr;50(4):247-272
pubmed: 29119848
Am J Med. 2003 Oct 1;115(5):343-51
pubmed: 14553868
Int J Infect Dis. 2016 Nov;52:43-48
pubmed: 27686727
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
PLoS One. 2015 Mar 23;10(3):e0121349
pubmed: 25799549
JAMA Intern Med. 2018 Feb 1;178(2):187
pubmed: 29181495
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
BMC Infect Dis. 2018 Dec 3;18(1):607
pubmed: 30509278
Qual Saf Health Care. 2003 Dec;12(6):458-64
pubmed: 14645763
JAMA. 2016 Feb 9;315(6):593-602
pubmed: 26864413
Thorax. 2010 Oct;65(10):878-83
pubmed: 20729231
PLoS One. 2014 Nov 25;9(11):e113825
pubmed: 25423037
BMC Pulm Med. 2017 Apr 20;17(1):66
pubmed: 28427381
Eur J Emerg Med. 2014 Dec;21(6):429-35
pubmed: 24384619
Arch Intern Med. 2000 Jan 10;160(1):98-104
pubmed: 10632310
Clin Infect Dis. 2001 Mar 1;32(5):728-41
pubmed: 11229840
Am J Infect Control. 2010 Sep;38(7):552-6
pubmed: 20400203
Infect Control Hosp Epidemiol. 2011 Apr;32(4):305-14
pubmed: 21460481
Am J Infect Control. 2014 Jan;42(1):34-7
pubmed: 24189326
BMC Med Res Methodol. 2018 Oct 3;18(1):100
pubmed: 30285737
JAMA Intern Med. 2019 Jul 8;:
pubmed: 31282921
Thorax. 2016 Mar;71(3):288-90
pubmed: 26197815
BMJ Qual Saf. 2015 Mar;24(3):228-38
pubmed: 25616279
Implement Sci. 2017 Nov 29;12(1):142
pubmed: 29187217
Crit Care Med. 2011 Oct;39(10):2218-24
pubmed: 21666444

Auteurs

Markus Fally (M)

Department of Internal Medicine, Section for Pulmonary Diseases, Herlev Gentofte Hospital, Hellerup, Denmark.

Christian von Plessen (C)

Unisanté, Lausanne, Switzerland.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Jacob Anhøj (J)

Centre of Diagnostic Investigation, Rigshospitalet, Copenhagen, Denmark.

Thomas Benfield (T)

Department of Infectious Diseases, Amager Hvidovre Hospital, Hvidovre, Denmark.

Britta Tarp (B)

Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark.

Lise Notander Clausen (LN)

Department of Respiratory and Infectious Diseases, Nordsjaellands Hospital, Hillerød, Denmark.

Lilian Kolte (L)

Department of Respiratory and Infectious Diseases, Nordsjaellands Hospital, Hillerød, Denmark.

Emma Diernaes (E)

Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark.

Line Molzen (L)

Department of Respiratory and Infectious Diseases, Nordsjaellands Hospital, Hillerød, Denmark.

Regitze Seerup (R)

Department of Infectious Diseases, Amager Hvidovre Hospital, Hvidovre, Denmark.

Simone Israelsen (S)

Department of Infectious Diseases, Amager Hvidovre Hospital, Hvidovre, Denmark.

Anne-Marie Blok Hellesøe (AB)

Centre of Diagnostic Investigation, Rigshospitalet, Copenhagen, Denmark.

Pernille Ravn (P)

Department of Internal Medicine, Section for Infectious Diseases, Herlev Gentofte Hospital, Hellerup, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH